Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
393 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Tuberculosis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Pipeline Review, H2 2016, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape. Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 7, 8, 61, 37 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 4, 5, 35 and 37 molecules, respectively.Tuberculosis. Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 7 Tuberculosis Overview 8 Therapeutics Development 9 Tuberculosis - Therapeutics under Development by Companies 11 Tuberculosis - Therapeutics under Investigation by Universities/Institutes 16 Tuberculosis - Pipeline Products Glance 19 Tuberculosis - Products under Development by Companies 23 Tuberculosis - Products under Investigation by Universities/Institutes 30 Tuberculosis - Companies Involved in Therapeutics Development 35 Tuberculosis - Therapeutics Assessment 99 Drug Profiles 111 Tuberculosis - Dormant Projects 345 Tuberculosis - Discontinued Products 356 Tuberculosis - Product Development Milestones 357 Appendix 371
List of Tables
Number of Products under Development for Tuberculosis, H2 2016 30 Number of Products under Development for Tuberculosis - Comparative Analysis, H2 2016 31 Number of Products under Development by Companies, H2 2016 32 Number of Products under Development by Companies, H2 2016 (Contd..1) 33 Number of Products under Development by Companies, H2 2016 (Contd..2) 34 Number of Products under Development by Companies, H2 2016 (Contd..3) 35 Number of Products under Development by Companies, H2 2016 (Contd..4) 36 Number of Products under Investigation by Universities/Institutes, H2 2016 37 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 38 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 39 Comparative Analysis by Late Stage Development, H2 2016 40 Comparative Analysis by Clinical Stage Development, H2 2016 41 Comparative Analysis by Early Stage Development, H2 2016 42 Comparative Analysis by Unknown Stage Development, H2 2016 43 Products under Development by Companies, H2 2016 44 Products under Development by Companies, H2 2016 (Contd..1) 45 Products under Development by Companies, H2 2016 (Contd..2) 46 Products under Development by Companies, H2 2016 (Contd..3) 47 Products under Development by Companies, H2 2016 (Contd..4) 48 Products under Development by Companies, H2 2016 (Contd..5) 49 Products under Development by Companies, H2 2016 (Contd..6) 50 Products under Investigation by Universities/Institutes, H2 2016 51 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 52 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 53 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 54 Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 55 Tuberculosis - Pipeline by Abera Bioscience AB, H2 2016 56 Tuberculosis - Pipeline by Akthelia Pharmaceuticals Limited, H2 2016 57 Tuberculosis - Pipeline by Alvogen Korea Co., Ltd., H2 2016 58 Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 59 Tuberculosis - Pipeline by Archivel Farma S.L., H2 2016 60 Tuberculosis - Pipeline by AstraZeneca Plc, H2 2016 61 Tuberculosis - Pipeline by Beech Tree Labs, Inc., H2 2016 62 Tuberculosis - Pipeline by BioDiem Ltd, H2 2016 63 Tuberculosis - Pipeline by BioLingus AG, H2 2016 64 Tuberculosis - Pipeline by Biomar Microbial Technologies, H2 2016 65 Tuberculosis - Pipeline by Bioversys AG, H2 2016 66 Tuberculosis - Pipeline by Celgene Corporation, H2 2016 67 Tuberculosis - Pipeline by Cellceutix Corporation, H2 2016 68 Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2016 69 Tuberculosis - Pipeline by Crestone, Inc., H2 2016 70 Tuberculosis - Pipeline by Dafra Pharma International Ltd., H2 2016 71 Tuberculosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 72 Tuberculosis - Pipeline by Demuris Limited, H2 2016 73 Tuberculosis - Pipeline by Eisai Co., Ltd., H2 2016 74 Tuberculosis - Pipeline by Eli Lilly and Company, H2 2016 75 Tuberculosis - Pipeline by Ensol Biosciences Inc., H2 2016 76 Tuberculosis - Pipeline by EpiVax, Inc., H2 2016 77 Tuberculosis - Pipeline by FIT Biotech Oy, H2 2016 78 Tuberculosis - Pipeline by GangaGen Inc., H2 2016 79 Tuberculosis - Pipeline by GlaxoSmithKline Plc, H2 2016 80 Tuberculosis - Pipeline by Globeimmune, Inc., H2 2016 81 Tuberculosis - Pipeline by Hager Biosciences, LLC, H2 2016 82 Tuberculosis - Pipeline by Hsiri Therapeutics LLC, H2 2016 83 Tuberculosis - Pipeline by Imaxio SA, H2 2016 84 Tuberculosis - Pipeline by Immunitor, Inc., H2 2016 85 Tuberculosis - Pipeline by ImmunoBiology Limited, H2 2016 86 Tuberculosis - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 87 Tuberculosis - Pipeline by Johnson & Johnson, H2 2016 88 Tuberculosis - Pipeline by Lakewood-Amedex Inc, H2 2016 89 Tuberculosis - Pipeline by Lipotek Pty Ltd., H2 2016 90 Tuberculosis - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 91 Tuberculosis - Pipeline by Microbion Corporation, H2 2016 92 Tuberculosis - Pipeline by Microbiotix, Inc., H2 2016 93 Tuberculosis - Pipeline by NEARMEDIC PLUS, Ltd, H2 2016 94 Tuberculosis - Pipeline by Novartis AG, H2 2016 95 Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016 96 Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 97 Tuberculosis - Pipeline by QureTech Bio AB, H2 2016 98 Tuberculosis - Pipeline by Recce Pty Ltd, H2 2016 99 Tuberculosis - Pipeline by Rodos BioTarget GmbH, H2 2016 100 Tuberculosis - Pipeline by Sanofi, H2 2016 101 Tuberculosis - Pipeline by Sanofi Pasteur SA, H2 2016 102 Tuberculosis - Pipeline by Sarepta Therapeutics, Inc., H2 2016 103 Tuberculosis - Pipeline by Sequella, Inc., H2 2016 104 Tuberculosis - Pipeline by Shionogi & Co., Ltd., H2 2016 105 Tuberculosis - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016 106 Tuberculosis - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016 107 Tuberculosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 108 Tuberculosis - Pipeline by TetraLogic Pharmaceuticals, H2 2016 109 Tuberculosis - Pipeline by TGV-Laboratories, H2 2016 110 Tuberculosis - Pipeline by Theravectys SA, H2 2016 111 Tuberculosis - Pipeline by Tomegavax, Inc., H2 2016 112 Tuberculosis - Pipeline by Transgene SA, H2 2016 113 Tuberculosis - Pipeline by TVAX Biomedical, Inc., H2 2016 114 Tuberculosis - Pipeline by Univalue Valorizacion, S.L., H2 2016 115 Tuberculosis - Pipeline by Vaccibody AS, H2 2016 116 Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H2 2016 117 Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd., H2 2016 118 Tuberculosis - Pipeline by Vichem Chemie Research Ltd., H2 2016 119 Assessment by Monotherapy Products, H2 2016 120 Assessment by Combination Products, H2 2016 121 Number of Products by Stage and Target, H2 2016 123 Number of Products by Stage and Mechanism of Action, H2 2016 126 Number of Products by Stage and Route of Administration, H2 2016 129 Number of Products by Stage and Molecule Type, H2 2016 131 Tuberculosis - Dormant Projects, H2 2016 366 Tuberculosis - Dormant Projects (Contd..1), H2 2016 367 Tuberculosis - Dormant Projects (Contd..2), H2 2016 368 Tuberculosis - Dormant Projects (Contd..3), H2 2016 369 Tuberculosis - Dormant Projects (Contd..4), H2 2016 370 Tuberculosis - Dormant Projects (Contd..5), H2 2016 371 Tuberculosis - Dormant Projects (Contd..6), H2 2016 372 Tuberculosis - Dormant Projects (Contd..7), H2 2016 373 Tuberculosis - Dormant Projects (Contd..8), H2 2016 374 Tuberculosis - Dormant Projects (Contd..9), H2 2016 375 Tuberculosis - Dormant Projects (Contd..10), H2 2016 376 Tuberculosis - Discontinued Products, H2 2016 377
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
